

SUCCESSOR-2:
A phase III trial of MeziKd for RRMM (NCT05552976)


N = 479
MeziKd (n = 288)
Kd (n = 191)

Primary endpoint: PFS. Key secondary endpoint: OS. Eligibility: RRMM with ≥1 prior LoT and PD; prior treatment including lenalidomide and an anti-CD38 mAb.

STUDY DESIGN

Stage 1 (dose optimization)*


Randomization 3:3:3:2 (N = 235)



Randomization 3:2
(N = 371)



Stage 2 (efficacy and safety)

Confirmatory analysis group (N = 479)




*Patients on nonselected Stage 1 Mezi doses could switch to the selected dose if eligible. †Included in the confirmatory analysis. ‡Dex dose reduction permitted for age >75 years, BMI <18.5 kg/m², poorly controlled diabetes, or prior steroid intolerance (MeziKd: 40→20 mg; Kd: 20→10 mg BW or 40→20 mg QW). §K dose on C1D1: 20 mg/m². ||QW dosing introduced July 2023.



EFFICACY



Treatment response



SAFETY



Oral mezigdomide + Kd significantly reduced the risk of death compared with Kd alone and demonstrated a safety profile consistent with previous studies. Neutropenia was manageable with dose modifications and/or G-CSF. These data support oral mezigdomide + Kd as a potential treatment option across diverse care settings, including community practice, for patients with ≥1 prior LoT who are exposed or refractory to lenalidomide and an anti-CD38 mAb.

BW, twice a week; C, cycle; CI, confidence interval; CR, complete response; D, day; G-CSF, granulocyte colony-stimulating factor; HR, hazard ratio; IV, intravenous; Kd, carfilzomib + dexamethasone; LoT, line of therapy; mAb, monoclonal antibody; MeziKd, mezigdomide + Kd; ORR, overall response rate; OS, overall survival; PD, progression of disease; PFS, progression-free survival; PR, partial response; RRMM, relapsed/refractory multiple myeloma; QW, once a week; sCR, stringent CR; TEAE, treatment-emergent adverse event; VGPR, very good PR.

Dimopoulos M. Oral Abstract #LB5004. EHA 2026 Congress; Jun 11–14, 2026; Stockholm, SE.